Drug Trial Radar · NCT05874401
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
302
Planned (sponsor's estimate)
Start
Oct 13, 2023
Primary completion
Feb 5, 2028
Study completion Feb 5, 2028
Sponsor
- Lead sponsor
- Pharmacosmos A/SIndustry
- Sponsor type
- Industry
- First posted
- May 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.
Conditions
- Extensive-stage Small-cell Lung Cancer
Interventions
TrilaciclibDrug
Participants will receive intravenous trilaciclib infusion
PlaceboDrug
Participants will receive intravenous placebo infusion
TopotecanDrug
Participants will receive intravenous topotecan infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: From date of randomization until date of death due to any cause for those who died; or date of last contact known as alive for those who survived in the study (censored cases), assessed up to 52 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.